

EVOTEC MAKES STRATEGIC EQUITY INVESTMENT IN ANTIBODY DRUG CONJUGATE SPECIALIST TUBULIS

- ▶ *EVOTEC PARTICIPATES IN SERIES B FINANCING ROUND OF ANTIBODY DRUG CONJUGATE SPECIALIST COMPANY TUBULIS*
- ▶ *TUBULIS WILL EXPAND ITS PLATFORM TECHNOLOGIES TO DEVELOP HIGHLY-TARGETED THERAPEUTICS FOR SOLID TUMOURS*

Hamburg, Germany, 03 May 2022:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has made a strategic equity investment in Tubulis GmbH by participating in the company's Series B financing round. Based in Munich, Germany, Tubulis specialises in the development of antibody drug conjugates ("ADCs") by leveraging a set of proprietary technology platforms to develop these highly targeted therapeutics against solid tumours.

By linking a small molecule drug ("payload") with an antibody, ADCs use the targeting capabilities of monoclonal antibodies to selectively deliver cancer-destroying substances to the affected cells. Tubulis' approach to ADCs is based on a variety of proprietary technologies regarding both linkers and payloads. The companies' technologies utilise novel chemical groups to go beyond traditional payload classes and increase antibody conjugation options, thus enabling the development of ADCs with higher drug-to-antibody ratios.

Evotec joins a consortium of new and renowned investors to fund Tubulis' € 60 m Series B financing round led by Andera Partners. Tubulis intends to use the new capital to further progress the company's proprietary pipeline as well as to continue innovating novel payload classes and identifying new targets for solid tumours to transform the ADC space. In conjunction with the financing round, Dr Thomas Hanke, EVP, Head of Academic Partnerships at Evotec, will join Tubulis' Supervisory Board.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are excited to participate in Tubulis' Series B financing round alongside European

venture capital investors such as Andera Partners and Fund+. This investment further adds momentum as well as diversification to Evotec’s **EVOequity** strategy.”

Dr Thomas Hanke, EVP Academic Partnerships at Evotec and new member of Tubulis’ Supervisory Board, commented: “With their unique, differentiated and proprietary platform of both linker and payload technologies, Tubulis is ideally positioned to fully exploit the potential that antibody drug conjugates hold within the field of targeted therapies also for solid tumours. This investment underpins Evotec’s strategic approach of leveraging partnerships to deliver effective medicines– regardless of therapeutic modality.”

ABOUT EVOTEC SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,200 highly qualified people. The Company’s 15 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter [@Evotec](https://twitter.com/Evotec) and [LinkedIn](https://www.linkedin.com/company/evotec).

FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based